Paulus H E, Bulpitt K J, Ramos B, Park G, Wong W K
University of California, Los Angeles, Schools of Medicine and Public Health, USA.
Arthritis Rheum. 2000 Dec;43(12):2743-50. doi: 10.1002/1529-0131(200012)43:12<2743::AID-ANR14>3.0.CO;2-A.
To evaluate factors that influence the responses defined by the American College of Rheumatology (ACR) 20% criteria for improvement in rheumatoid arthritis (RA).
ACR 20% and 50% response rates were calculated from data collected for the intervals 0-6, 0-12, and 0-24 months for 180 RA patients participating in the Western Consortium of Practicing Rheumatologists long-term observational study of early seropositive RA (mean +/- SD duration of RA at study entry 6.0 +/- 3.4 months). Analyzable cases were patients with paired data for tender and swollen joint counts plus at least 3 of the following criteria: physician's and patient's global assessments of disease activity and patient's score for pain (by visual analog scale), physical function score on the Health Assessment Questionnaire (HAQ), and levels of an acute-phase reactant. Response rates were then recalculated by 3 different methods: 1) using only cases with complete paired data for all criteria, 2) sequentially assuming no improvement in each of the 5 secondary criteria, and 3) substituting grip strength for HAQ scores.
Using 464 paired observations for all analyzable cases, ACR 20% (50%) improvement rates were 52.6% (33.0%), compared with 55.6% (34.8%) for 365 paired observations from the cases with complete data. Decreases in ACR response rates when secondary criteria were sequentially set at "no improvement" ranged from 11.7% (pain at 0-6 months) to 1.2% (C-reactive protein at 0-12 months), but these were not statistically different by the kappa statistic. Overall numerical rankings of the relative contributions of the secondary criteria to the ACR 20% or 50% response rates were physician's global assessment, pain, HAQ, patient's global assessment, and acute-phase reactant. Only 7.8% of paired grip strength observations showed > or =20% improvement, compared with 71% of paired HAQ observations.
The use of all "analyzable" cases (paired data for tender and swollen joint counts plus > or =3 of the 5 secondary criteria) increases the number of subjects and only slightly decreases the ACR response rate compared with analyses limited to cases with complete data. The contributions of the secondary criteria are not statistically different, supporting their equal weighting in the ACR definition of improvement. The ACR 20% response rates are higher when the HAQ, rather than grip strength, is used to measure physical function.
评估影响美国风湿病学会(ACR)制定的类风湿关节炎(RA)改善20%标准所定义反应的因素。
从参与西部执业风湿病学家联盟早期血清阳性RA长期观察研究的180例RA患者(研究入组时RA的平均病程±标准差为6.0±3.4个月)在0至6个月、0至12个月和0至24个月期间收集的数据中计算ACR 20%和50%的反应率。可分析病例为有压痛和肿胀关节计数配对数据且至少满足以下3项标准的患者:医生和患者对疾病活动的整体评估、患者疼痛评分(采用视觉模拟量表)、健康评估问卷(HAQ)的身体功能评分以及急性期反应物水平。然后通过3种不同方法重新计算反应率:1)仅使用所有标准均有完整配对数据的病例;2)依次假设5项次要标准中的每项均无改善;3)用握力替代HAQ评分。
对所有可分析病例使用464对观察数据时,ACR 20%(50%)的改善率分别为52.6%(33.0%),而来自有完整数据病例的365对观察数据的改善率为55.6%(34.8%)。当次要标准依次设定为“无改善”时,ACR反应率的降低范围为11.7%(0至6个月时的疼痛)至1.2%(0至12个月时的C反应蛋白),但通过kappa统计量分析这些差异无统计学意义。次要标准对ACR 20%或50%反应率相对贡献的总体数值排名依次为医生的整体评估、疼痛、HAQ、患者的整体评估和急性期反应物。仅7.8%的握力配对观察数据显示改善≥20%,而HAQ配对观察数据的这一比例为71%。
与仅限于有完整数据病例的分析相比,使用所有“可分析”病例(压痛和肿胀关节计数的配对数据以及5项次要标准中的≥3项)可增加受试者数量,且仅略微降低ACR反应率。次要标准对反应率的贡献无统计学差异,支持它们在ACR改善定义中权重相等。当使用HAQ而非握力来测量身体功能时,ACR 20%的反应率更高。